Across TCGA pan-cancer cohorts, EDARADD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EDARADD data layer compared with 19 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EDARADD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EDARADD expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where EDARADD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.753	0.447	<.001	75	view →
LSCC	OS	Median	All	1.000	0.936	.010	13	view →
LUAD	DFS	Quartile	II,III,IV	0.780	0.270	.020	5	view →
UCEC	DFS	Tertile	All	0.807	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: EDARADD tumor-vs-normal RNA expression · all EDARADD data types